Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy | Zendy

Sidonie Lambert-Niclot | Zendy; C. Charpentier | Zendy; Alexandre Storto | Zendy; Djeneba Fofana | Zendy; Cathia Soulié | Zendy; Slim Fourati | Zendy; Marc Wirden | Zendy; Laurence MorandJoubert | Zendy; Bernard Masquelier | Zendy; Philippe Flandre | Zendy; Vincent Cálvez | Zendy; Diane Descamps | Zendy; AnneGeneviève Marcelin | Zendy

Open Access

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

Author(s) -

Sidonie Lambert-Niclot,

C. Charpentier,

Alexandre Storto,

Djeneba Fofana,

Cathia Soulié,

Slim Fourati,

Marc Wirden,

Laurence MorandJoubert,

Bernard Masquelier,

Philippe Flandre,

Vincent Cálvez,

Diane Descamps,

AnneGeneviève Marcelin

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt463

Subject(s) - rilpivirine , emtricitabine , tenofovir , medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , antiretroviral drug , antiretroviral agents , drug resistance , virology , viral load , biology , microbiology and biotechnology

In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this study was to describe rilpivirine, tenofovir and emtricitabine resistance in HIV-1-infected patients who experienced virological failure during their previous antiretroviral treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research